The stock of Translate Bio, Inc. (NASDAQ:TBIO) has been Initiated to Buy by Jefferies in its latest research note that was published on July 22. TBIO was given a price target of $20, with other Wall Street analysts also giving their reports regarding the stock. ROTH Capital, analysts launched coverage of TBIO stock with a Buy rating, according to their flash note to investors on June 18
Translate’s stock is covered by 6 analysts, with 3 of them rating the stock as Buy. It has been deemed to have strong buy by 3 of the analysts, none of them have rated it as a Hold while none of them rated it as sell. The situation was different a month ago when the stock was rated as a Buy by only 2 analysts. 2 of them rated it as strong buy with none of them recommended investors to Hold on to the stock. Meanwhile, none analyst(s) rated it as a sell. The above data shows that TBIO has an average analyst rating of 1.50.
Translate Bio, Inc., which has current market capitalization of above $418 Million, published its last quarter earnings on June 30, 2019. The company was able to amass $7.17 million in revenue. This figure is $5.44 million more than what analysts had expected which was $1.73 million. During the first quarter of the year, Translate also recorded $-0.74 earnings per share (EPS) which is $0.26 above the $-0.48 estimated by Thomson Reuter’s analyst, leading to a surprise factor of -54.97%.
TBIO surged by $0.31 during the normal trading session on Tuesday and reaching a high of $8.31 during the day while it closed the day at $8.24. The Translate stock had a low trading volume of 0.25 million shares on that day, which is low compared to the average daily volume of 237.29M shares. TBIO has also gained 1.48% of its value over the past 7 days. However, the stock has declined by 19.77% in the 3 months of the year. Over the past six months meanwhile, it has gained 13.97% while it has added 9.87% year-on date. Let us now take a look at the stock’s potential support and resistance levels. The publicly traded company was seen to have slipped by -40.72% from its 3 months high price. However, taking another look at TBIO will indicate that it is trading +5.91% away from its 90-day low. Looking at the bigger picture, the Translate Bio, Inc. stock has dropped by -42.52% from its 52-week high while it has surged by +71.31% from its 52-week low price.
Translate has around 76 Billion cash on their books at the moment. This figure will have to be compared and looked into, with their current liabilities standing at $20 Billion. The Translate stock is bringing in revenue of over 12 months, which is roughly 44 Billion. Despite all that, Translate Bio, Inc. is seeing things progressing very much as their y-o-y quarterly revenue surged by 0.84%.
Looking at the stock’s Technical analysis information over the past 50 days shows that its Raw Stochastic average stood at 7.52%. This figure is worse than the company’s 20-day Raw Stochastic average which currently stands at 20.72%. Over the past 20 days, Translate’s Stochastic %K stood at 15.15% while its Stochastic %D was revealed to be 13.44%.